Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)

Real-time Quote. Real-time Tradegate - 02/12 03:26:18 pm
73.605 EUR   +3.02%
02/10 UCB : Enters into Research Agreement with Baylor College of Medicine
02/09 UCB : and Baylor College of Medicine launch strategic alliance in ne..
02/01 UCB : Executive Committee welcomes a new member
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
02/08/2016 02/09/2016 02/10/2016 02/11/2016 02/12/2016 Date
69.38(c) 70.11(c) 71.51(c) 71.45(c) 73.49 Last
399 029 395 482 372 987 365 791 341 459 Volume
-4.63% +1.05% +2.00% -0.08% +2.86% Change
More quotes
Financials (€)
Sales 2015 3 727 M
EBIT 2015 589 M
Net income 2015 445 M
Debt 2015 1 158 M
Yield 2015 1,58%
Sales 2016 3 993 M
EBIT 2016 666 M
Net income 2016 412 M
Debt 2016 1 128 M
Yield 2016 1,70%
P/E ratio 2015 30,11
P/E ratio 2016 32,21
EV / Sales 2015 4,04x
EV / Sales 2016 3,76x
Capitalization 13 897 M
More Financials
Company
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.It offers medicinal products for central nervous system and immunology disorders under the Cimzia, Xyzal, Zyrtec, Tussionex, Lortab, Vimpat, Keppra, and Neupro.The company was founded by... 
Sector
Pharmaceuticals
Calendar
02/26Earnings Release
More about the company
Surperformance© ratings of UCB
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB
02/10 UCB : Enters into Research Agreement with Baylor College of Medicine
02/09 UCB : and Baylor College of Medicine launch strategic alliance in neurodegenerat..
02/01 UCB : Executive Committee welcomes a new member
02/01 UCB : new epilepsy drug BRIVIACT® receives EU approval
02/01 UCB : Transparency notification
01/11 UCB : Transparency notification
2015 UCB : New Findings from UCB Pharma SA in the Area of Economic Dynamics Described..
2015 UCB : Transparency notification from BlackRock Inc
More news
Sector news : Pharmaceuticals - NEC
10:05aDJLILLY : U.K. Court Rules in Opponent's Favor on Alimta Patent
09:56aDJLILLY : U.K. Court Rules in Opponent's Favor on Alimta Patent
09:36a NOVARTIS : Sandoz Acquires Rights of Biosimilar Infliximab from Pfizer
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/08 Wobbles Aside, Small Pharma Shares Broadly On The Up In 2015
2015 THE ISHARES MSCI BELGIUM CAPPED ETF : What's In A Name?
2015 WEEK IN REVIEW : GuaHao Raises $395 Million For China Internet Healthcare
2015 Amgen's osteoporosis candidate successful in late stage study
2015 UCB's (UCBJF) CEO Jean-Christophe Tellier on Q2 2015 Results - Earnings Call ..


Comments 
Advertisement
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Full-screen chart
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions